Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Why GoPro Stock Skyrocketed This Week (Fool) +++ GOPRO Aktie +3,33%

BIOXCEL Aktie

 >BIOXCEL Aktienkurs 
3.38 EUR    -3.8%    (Tradegate)
Ask: 3.47 EUR / 2200 Stück
Bid: 3.39 EUR / 890 Stück
Tagesumsatz: 2103 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
BIOXCEL Aktie über LYNX handeln
>BIOXCEL Performance
1 Woche: -20,5%
1 Monat: 0%
3 Monate: 0%
6 Monate: 0%
1 Jahr: 0%
laufendes Jahr: 0%
>BIOXCEL Aktie
Name:  BIOXCEL THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09075P2048 / A40YSR
Symbol/ Ticker:  BX20 (Frankfurt) / BTAI (NASDAQ)
Kürzel:  FRA:BX20, ETR:BX20, BX20:GR, NASDAQ:BTAI
Index:  -
Webseite:  https://www.bioxceltherap..
Profil:  BioXcel Therapeutics, Inc., together with its subs..
>Volltext..
Marktkapitalisierung:  51.11 Mio. EUR
Unternehmenswert:  127.82 Mio. EUR
Umsatz:  0.74 Mio. EUR
EBITDA:  -41.78 Mio. EUR
Nettogewinn:  -43.63 Mio. EUR
Gewinn je Aktie:  -10.85 EUR
Schulden:  93.3 Mio. EUR
Liquide Mittel:  15.91 Mio. EUR
Operativer Cashflow:  -47.76 Mio. EUR
Bargeldquote:  0.56
Umsatzwachstum:  -67.16%
Gewinnwachstum:  57.04%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  BIOXCEL
Letzte Datenerhebung:  29.08.25
>BIOXCEL Kennzahlen
Aktien/ Unternehmen:
Aktien: 14.56 Mio. St.
Frei handelbar: 90.72%
Rückkaufquote: -34.54%
Mitarbeiter: 37
Umsatz/Mitarb.: 0.05 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 392.72%
Bewertung:
KGV: -
KGV lG: -
KUV: 36.93
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -179.72%
Gewinnmarge: -5869.82%
Operative Marge: -5655.41%
Managementeffizenz:
Gesamtkaprendite: -111.7%
Eigenkaprendite: -
>BIOXCEL Peer Group

Es sind 601 Aktien bekannt.
 
27.08.25 - 14:30
 BioXcel whipsaws after late-stage trial win for lead asset (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.08.25 - 14:03
 UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® (GlobeNewswire EN)
 
BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia...
27.08.25 - 13:48
 XFRA: BX20: Wiederaufnahme/Resumption (XETRA)
 
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIOXCEL THERAP.INC.NEW BX20 US09075P2048 AB/FROM ONWARDS 27.08.2025 13:42 CET...
27.08.25 - 13:31
 XFRA: BX20: Aussetzung/Suspension (XETRA)
 
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL BIOXCEL THERAP.INC.NEW BX20 US09075P2048 BAW/UFN...
27.08.25 - 13:31
 XFRA: INSTRUMENT_SUSPENSION - US09075P2048 (XETRA)
 
Instrument ID [22619230] (BX20 - US09075P2048) suspended...
27.08.25 - 13:03
 BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® (GlobeNewswire EN)
 
BXCL501 achieved SERENITY At-Home's primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia...
27.08.25 - 10:51
 BioXcel Stock Surges 19% In After-Hours Trading: What You Need To Know (Benzinga)
 
BioXcel Therapeutics shares surged over 19% after hours ahead of key Phase 3 trial results for its at-home agitation treatment, sparking strong investor interest. read more...
26.08.25 - 22:03
 BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 (GlobeNewswire EN)
 
Company to host conference call at 8 a.m. ET, August 27, 2025 Company to host conference call at 8 a.m. ET, August 27, 2025...
18.08.25 - 13:03
 BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire EN)
 
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting...
18.08.25 - 12:01
 XFRA: BX20: Wiederaufnahme/Resumption (XETRA)
 
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIOXCEL THERAP.INC.NEW BX20 US09075P2048 AB/FROM ONWARDS 18.08.2025 11:54 CET...
16.08.25 - 15:45
 BTAI Delivers Over 300% In Less Than 2 Months - SERENITY At-Home Trial Data Due This Month (RTTNews)
 
BioXcel Therapeutics Inc. (BTAI) has a clinical trial catalyst to watch this month, related to its lead drug, IGALMI, in an expanded indication....
13.08.25 - 13:03
 BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series (GlobeNewswire EN)
 
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a virtual fireside chat on Thursday, August 14, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series....
12.08.25 - 22:45
 BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
 
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...
12.08.25 - 14:03
 BioXcel Therapeutics GAAP EPS of -$2.45 misses by $0.59, revenue of $0.12M misses by $0.09M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.08.25 - 13:57
 BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire EN)
 
Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August...
06.08.25 - 13:03
 BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies (GlobeNewswire EN)
 
Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitation...
21.07.25 - 13:03
 BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI® (GlobeNewswire EN)
 
Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Trenne alles, was eigentlich Geschäft ist, vom Leben. - Johann Wolfgang von Goethe
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!